Company: PRTA
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001559053-25-000023
Chunk: 20

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
 the transaction, NNL ceased to be a related party of PBL. The aggregate purchase price consisted of an upfront payment of $ 60.0

Should Novo Nordisk achieve certain stages of development or commercialization for products or product candidates containing coramitug(formerlyPRX004) or a derivative thereof in ATTR amyloidosis, PBL is entitled to receive certain milestone payments based on specified development and commercial milestones. The development and commercialization milestone payments will be discounted if the milestone events are achieved with respect to other indications. Should Novo

Nordisk achieve specified thresholds of worldwide, annual net sales of the milestone products, regardless of indication, PBL will also be entitled to receive specified one-time net sales milestone payments. All milestone payments attributable to an achieved milestone will be paid to PBL, subject to Novo Nordisk’s offset right for indemnity claims or unpaid amounts in respect of any purchase price adjustment.

The u pfront payment of $ 60.0 0.7

Contingent Consideration/Milestone Accounting

In December 2022, the Company received a $ 40.0

The Company is eligible to receive additional development and sales milestone payments from Novo Nordisk totaling up to $ 1.13 The Company did not achieve any development and sales milestones under this share purchase agreement during the three months ended March 31, 2025 and 2024, respectively.

The Company excluded the milestone payments in the initial transaction price because such payments are considered to be variable considerations with constraint. Such milestone payments will be recognized as revenue at a point in time when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.

Revenue Recognition

Noe three months ended March 31, 2025 and 2024, respectively. The Company had noMarch 31, 2025, and December 31, 2024, respectively.

8. Shareholders' Equity

Ordinary Shares

As of March 31, 2025, the Company had 100,000,000 0.01 d53,826,982or dinary shares issued and outstanding. Each ordinary share is entitled to one 15,189,888

Euro Deferred Shares

As of March 31, 2025, the Company had 10,000 22 No pari passu with the ordinary shares and are treated as a single class in all respects.

At-the-Market Offerings

In December 2021, the Company entered into